Luann Phillips
Overview
Explore the profile of Luann Phillips including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Raoufinia A, Bihorel S, Passarell J, Mallikaarjun S, Phillips L
Clin Pharmacol Drug Dev
. 2022 Jan;
11(2):150-164.
PMID: 34979059
An intramuscular formulation of aripiprazole monohydrate dosed once monthly (AOM) was developed to address nonadherence with the approved oral tablets. A 3-compartment linear population pharmacokinetic model for oral and AOM...
2.
Periclou A, Phillips L, Ghahramani P, Kapas M, Carrothers T, Khariton T
Eur J Drug Metab Pharmacokinet
. 2020 Nov;
46(1):53-69.
PMID: 33141308
Background And Objectives: Cariprazine, a dopamine D-preferring D/D receptor partial agonist, is approved for the treatment of adults with schizophrenia (1.5-6 mg/day) and manic/mixed (3-6 mg/day) episodes associated with bipolar...
3.
Andrews K, Wesche D, McCarthy J, Mohrle J, Tarning J, Phillips L, et al.
Annu Rev Pharmacol Toxicol
. 2017 Oct;
58:567-582.
PMID: 28992431
Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate...
4.
Sunkaraneni S, Blum D, Ludwig E, Chudasama V, Fiedler-Kelly J, Marvanova M, et al.
Clin Pharmacol Drug Dev
. 2017 Sep;
7(3):287-297.
PMID: 28881418
Given the potential consequences of antiepileptic therapy nonadherence, missed-dose scenarios of 12- to 48-hour dose delays (4-hour intervals) for eslicarbazepine acetate monotherapy were evaluated using simulated plasma concentrations of a...
5.
Darwish M, Megason G, Bond M, Hellriegel E, Robertson Jr P, Grasela T, et al.
Curr Med Res Opin
. 2014 Aug;
30(11):2305-15.
PMID: 25105914
Objective: The pharmacokinetic (PK) profile of bendamustine has been characterized in adults with indolent non-Hodgkin lymphoma (NHL), but remains to be elucidated in pediatric patients with hematologic malignancies. This analysis...
6.
Darwish M, Burke J, Hellriegel E, Robertson Jr P, Phillips L, Ludwig E, et al.
Cancer Chemother Pharmacol
. 2014 Mar;
73(6):1119-27.
PMID: 24677018
Purpose: Bendamustine plus rituximab has been reported to be effective in treating lymphoid malignancies. This analysis investigated the potential for drug-drug interactions between the drugs in patients with indolent non-Hodgkin...
7.
Van Wart S, Phillips L, Ludwig E, Russo R, Gajjar D, Bello A, et al.
Antimicrob Agents Chemother
. 2004 Nov;
48(12):4766-77.
PMID: 15561855
Garenoxacin (T-3811ME, BMS-284756) is a novel, broad-spectrum des-F(6) quinolone currently under study for the treatment of community-acquired respiratory tract infections. This analysis assessed garenoxacin population pharmacokinetics and exposure-response relationships for...